NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Technology Appraisal (Committee B) meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 10 December 2020

**Location:** Zoom

## **Committee members present:**

1. Professor Amanda Adler (Chair) Present for all items
2. Dr Sanjeev Patel (Vice Chair) Present for all items
3. Dr Carlo Berti Present for all items
4. Dr Laura Bojke Present for items 1 to 5
5. Mr Mark Chapman Present for items 1 to 5
6. Dr Mark Glover Present for all items
7. Dr Megan John Present for all items
8. Dr Sanjay Kinra Present for items 4 to 7
9. Dr Nicholas Latimer Present for all items
10. Dr Rhiannon Owen Present for all items
11. Ms Anna Pracz Present for all items
12. Dr Stephen Smith Present for all items
13. Professor Nicky Welton Present for all items
14. Mr Nigel Westwood Present for all items
15. Mr Peter Wheatley-Price Present for items 1 to 5
16. Professor Sarah Wild Present for all items
17. Dr Stuart Williams Present for items 1 to 4
18. Dr Ed Wilson Present for all items
19. Mr Tony Wootton Present for all items

## **NICE staff present:**

Henry Edwards, Associate Director Present for items 1 to 5

Nicole Elliott, Associate Director Present for items 6 and 7

Jeremy Powell, Project Manager Present for all items

Ellie Donegan, HTA Adviser Present for items 1 to 4

Carl Prescott, HTA Adviser Present for item 5

Laura Dunning, HTA Adviser Present for items 6 and 7

Charlie Hewitt, HTA Analyst Present for items 1 to 4

Hannah Nicholas, HTA Analyst Present for item 5

Mary Hughes, HTA Analyst Present for items 6 and 7

Mira Patel, COT Coordinator Present for all items

Gemma Smith, COT Coordinator Present for all items

Heidi Livingstone, PIP Adviser Present for items 1 to 4.1, 5.1 and 6.1

Rosalee Mason, MIP Coordinator Present for items 1 to 4.1, 5.1 and 6.1

Sophie McHugh, COT Administrator Present for all items

## **External group representatives present:**

Robert Hodgson, Research Fellow, Centre for Reviews Present for items 1 to 4.2

 and Dissemination and Centre for Health Economics, York

Sahar Sharif, Research Fellow, Centre for Reviews Present for items 1 to 4.2

 and Dissemination and Centre for Health Economics, York

James Mahon, Health Economist, Liverpool Reviews and Present for items 5.1 and 5.2

 and Implementation Group (LRiG)

Sarah Nevitt, Research Associate (Medical Statistician), Present for items 5.1 and 5.2

 Liverpool Reviews and Implementation Group (LRiG)

Graham Scotland, Reader – Decision Science, Aberdeen Present for item 6.1

 HTA

## **Professional experts present:**

Dr Andrew Pink, clinical expert, Consultant Dermatologist, Present for items 1 to 4.1

 St John’s Institute of Dermatology, Guy’s & St. Thomas’

 NHS Foundation Trust, nominated by Eli Lilly

Dr Richard Weller, clinical expert, Honorary Consultant Present for items 1 to 4.1

 Dermatologist, University of Edinburgh and NHS Lothian,

 nominated by British Association of Dermatologists

Alice Lambert, patient expert, Head of Services, Present for items 1 to 4.1

 National Eczema Society (NES), nominated by NES

James Pitayanukul, patient expert, trustee of Present for items 1 to 4.1

 National Eczema Society, nominated by NES

Dr Eli Siber, clinical expert, Consultant Neurologist, Present for item 5.1

 Kings College Hospital, nominated by MS Trust

Dr Victoria Williams, clinical expert, Consultant Neurologist, Present for item 5.1

 Guy’s and St Thomas’ NHS Trust, nominated by

 Association of British Neurologists

Lorraine Hazelhurst, patient expert, nominated by Present for item 5.1

 MS Society

Tracey Nicholson, patient expert, nominated by MS Trust Present for item 5.1

Malcolm Quaile, commissioning expert, NHS England Present for item 5.1

Professor Nicholas James, clinical expert, Professor of Present for item 6.1

 Clinical Oncology, UHB, nominated by Janssen

Professor Noel Clarke, clinical expert, Professor of Present for item 6.1

 Urological Oncology, The Christie and Salford Royal

 Hospitals, nominated by British Association of Urological

 Surgeons

Heather Blake, clinical expert, Director of Support and Present for item 6.1

 Influencing, Prostate Cancer UK, nominated by

 Prostate Cancer UK

Peter Clark, CDF Clinical lead, NHSE, Present for item 6

## **Observers present:**

Helen Barnett, Senior Editor, NICE, Present for item 6

Sarah Bromley, Senior Editor, NICE Present for items 1 to 4

Ella Livingstone, Technical Adviser, NICE Present for all items

Claire Khouja, Research Fellow, Centre for Reviews Present for items 1 to 4.1 and 5.1

 and Dissemination York

Ann Greenwood, Senior Editor, NICE Present for item 5

Edgar Masanga, Business Analyst – RIA, NICE Present for item 6

Sumayya Answer, Research Fellow, Centre for Present for item 5.1

 Reviews and Dissemination York

## **Notes**

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Veline L’Esperance.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. No minutes were approved at this meeting.

### Appraisal of Baricitinib for treating moderate to severe atopic dermatitis [ID1622]

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Eli Lilly
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Alice Lambert, clinical expert, declared an indirect interest as she has worked at the National Eczema Society since 19 June 2017 and has worked as a corporate sponsor of Eli Lilly since 2019. It was agreed that these declarations would not prevent her from participating in this section of the meeting.
* Dr Andrew Pink declared a direct and indirect interest as he has been advisor, speaker for Eli Lilly and has acted as Principal Investigator on Eli Lilly clinical trials. It was agreed that these declarations would not prevent him from participating in this section of the meeting
* Dr Richard Weller declared a direct interest as he has served on an advisory panel for Lilly for which he received payment. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
* No further conflicts of interest were declared for this appraisal.
	1. Part 2a – Closed session (members of the public, experts and the company representatives were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (external group representatives were asked to leave the meeting)
		1. The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

### Appraisal of Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Celgene/BMS.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Nicholas Latimer, committee member, declared financial interests as he has received payment from Merck Serono for providing a talk on methods for modelling treatment sequences in an ISPOR webinar. The talk was not specific to any drugs or disease areas. It was agreed that this declaration would not prevent Dr Latimer from participating in this section of the meeting.
* No further conflicts of interest were declared for this item.
	1. Part 2a – Closed session (members of the public, experts and company representatives were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (external group representatives were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

### Appraisal of Abiraterone for treating newly diagnosed metastatic hormone-naive prostate cancer [ID945]

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Janssen.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Mr Peter Wheatley Price, committee member, declared financial interests as Takeda is a manufacturer for Leuprorelin which is actively promoted in prostate cancer. It was agreed that this declaration would prevent Mr Wheatley-Price from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
* No conflicts of interest were declared for this item.
	1. Part 2 - Closed session (members of the public, experts, external group representatives and company representatives were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
		2. The committee then agreed on the content of the Appraisal Consultation Document (ACD). The committee decision was reached by consensus.
		3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal (Committee B) will be held on Thursday 7 January 2021 and will start promptly at 9:30am.